Post TAVI pacemaker implantation does not increase mortality

Original Title: Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. A Systematic Review and Meta-Analysis. Reference: Ander Regueiro et al. Circ Cardiovasc Interv. 2016 May;9(5).   Available data on the clinical impact of the new-onset left bundle branch block (LBBB) and<a href="https://solaci.org/en/2016/05/30/post-tavi-pacemaker-implantation-does-not-increase-mortality/" title="Read more" >...</a>

Low risk patients: TAVI or surgical replacement?

Original Title: Transcatheter Aortic Valve Implantation Compared With Surgical Aortic Valve Replacement in Low-Risk Patients. Reference: Stefano Rosato et al. Circ Cardiovasc Interv. 2016 May;9(5):e003326. The proved efficacy of transcatheter aortic valve implantation (TAVI) in high risk patients is leading the expansion of its indication for lower risk patients. All the same, compared to the<a href="https://solaci.org/en/2016/05/27/low-risk-patients-tavi-or-surgical-replacement/" title="Read more" >...</a>

VII Latin American Symposium on Structural Cardiomyopathy

Do you need an update on Structural Cardiomyopathy? If so, clear your schedule from July 27 thru 29. We are hosting the 7th Latin American Symposium on Structural Cardiomyopathy, to be held at the Intercontinental Hotel in Cali, Colombia, organized by Angiografía de Occidente S.A. Featuring lectures of national and international relevance and the presence<a href="https://solaci.org/en/2016/05/27/vii-latin-american-symposium-on-structural-cardiomyopathy/" title="Read more" >...</a>

TriGuard: NeuroProtection Device during TAVI

Original Title: A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement. Presenter: Alexandra Lansky   This work was designed to assess the safety and efficacy of the TriGuard device as a complement during transcatheter aortic valve implantation (TAVI) compared to no protection in a<a href="https://solaci.org/en/2016/05/20/triguard-neuroprotection-device-during-tavi/" title="Read more" >...</a>

TAVI at 10 Years: First Study to Assess TAVI Long Term Durability

Original Title: First look at long-term durability of transcatheter heart valves: Assessment of valve function up to 10 years after implantation. Presenter: Danny Dvir.   Transcatheter aortic valve implantation (TAVI) is being used in increasingly younger patients at low surgical risk, which is why longer survival is expected. The durability of transcatheter aortic prostheses has<a href="https://solaci.org/en/2016/05/19/tavi-at-10-years-first-study-to-assess-tavi-long-term-durability/" title="Read more" >...</a>

Evaluación Hemodinámica de la Insuficiencia Aórtica post TAVR

Hemodynamic assessment of post TAVR aortic regurgitation

Original Title: Hemodynamic Assessment of Aortic Regurgitation after Transcatheter Aortic Valve Replacement – The Diastolic Pressure-Time Index. Reference: Robert Höllriegel et al. JACC Cardiovasc Interv. 2016 Apr 16.   Courtesy of Dr. Agustín Vecchia.   In 2012 Sinning and collaborators presented a study in the “Journal of the American College of Cardiology” about an index<a href="https://solaci.org/en/2016/05/09/hemodynamic-assessment-of-post-tavr-aortic-regurgitation/" title="Read more" >...</a>

TAVI in asymptomatic severe aortic stenosis?

Original Title: Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptomatic severe aortic stenosis. Reference: Généreux P et al. J Am Coll Cardiol. 2016; Epub ahead of print.   Given that transcatheter aortic valve replacement (TAVI) is now being prescribed to lower risk patients, some wonder whether it is time to study the benefit<a href="https://solaci.org/en/2016/04/24/tavi-in-asymptomatic-severe-aortic-stenosis/" title="Read more" >...</a>

MitraClip: Should we prescribe it earlier?

Courtesy of Dr. Carlos Fava. Patients with severe mitral regurgitation unfit for surgery due to high surgical risk are likely to develop chronic kidney disease (CKD). There is limited information available on patients with CKD receiving MitraClip.   This study analyzed patients receiving MitraClip and presenting chronic kidney disease.   CKD was defined as a<a href="https://solaci.org/en/2016/04/19/mitraclip-should-we-prescribe-it-earlier/" title="Read more" >...</a>

TAVR with Sapien XT: similar to surgical replacement in intermediate risk patients

Original Title: Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. PARTNER 2A. Reference: Martin B. Leon et al. NEJM April 2, 2016 Courtesy of Dr. Juan A. Terré Studies have shown mortality rates after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in high risk patients are similar (PARTNER 2 – Cohort B). This is<a href="https://solaci.org/en/2016/04/15/tavr-with-sapien-xt-similar-to-surgical-replacement-in-intermediate-risk-patients/" title="Read more" >...</a>

TAVI in Low-Flow / Low-Gradient

Original Title: Transcatheter Aortic Valve Implantation for Paradoxical Low-Flow Low-Gradient Aortic Stenosis Patients. Reference: Nicolas Debry et al. Catheter Cardiovasc Interv. 2016 Mar;87(4):797-804. Courtesy of Dr. Carlos Fava. Approximately 10 to 13% of low-flow low-gradient severe aortic stenosis cases (LF-LG) have preserved left ventricular function. Its physiopathology remains unclear and it has been associated with a<a href="https://solaci.org/en/2016/04/14/tavi-in-low-flow-low-gradient/" title="Read more" >...</a>